• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 3-pyridinecarbonitriles

1-3-(dimethylamino)propyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile: A Multifunctional Compound with Promising Therapeutic Potential

1-3-(dimethylamino)propyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (CAS No. 40859-37-8) represents a novel class of synthetic molecules with unique structural features that have garnered significant attention in recent years. This compound, characterized by its 1,2-dihydropyridine core and the presence of multiple functional groups such as hydroxyl, methyl, and carbonitrile moieties, exhibits potential applications in pharmaceutical research. Recent studies have highlighted its ability to modulate intracellular signaling pathways, making it a candidate for therapeutic interventions in neurodegenerative disorders and metabolic diseases.

The 1,2-dihydropyridine scaffold is a well-established pharmacophore in the development of calcium channel blockers, but the incorporation of dimethylamino and hydroxyl groups in this molecule introduces novel biological activities. Researchers have demonstrated that the 6-hydroxy substitution enhances the compound's solubility and bioavailability, while the 4-methyl group contributes to its stability in biological systems. These structural modifications are critical for optimizing the therapeutic profile of 1-3-(dimethylamino)propyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile.

Recent advancements in medicinal chemistry have focused on the synthesis of 1,2-dihydropyridine-derived compounds with improved pharmacokinetic properties. A 2023 study published in Journal of Medicinal Chemistry reported that the carbonitrile group in 1-3-(dimethylamino)propyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile plays a key role in its interaction with target receptors. This functional group is believed to enhance the molecule's ability to cross cell membranes, thereby improving its efficacy in targeting intracellular pathways.

One of the most intriguing aspects of 1-3-(dimethylamino)propyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile is its potential to modulate the endothelin-1 signaling pathway, which is implicated in hypertension and cardiovascular diseases. Preclinical studies have shown that this compound can inhibit the activity of endothelin-converting enzyme, leading to reduced vascular resistance. This finding aligns with the growing interest in developing endothelin receptor antagonists for the treatment of cardiorenal syndromes.

Another area of research focuses on the 1,2-dihydropyridine core's ability to interact with calcium channels in neuronal cells. A 2022 study in Neuropharmacology revealed that 1-3-(dimethylamino)propyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile exhibits selective antagonism against L-type calcium channels, which could have implications for the treatment of epilepsy and neuroinflammation. This property is particularly valuable given the limited options available for managing refractory seizures.

From a synthetic perspective, the 1,2-dihydropyridine ring system is often synthesized via the Biginelli reaction, a multicomponent reaction that allows for the efficient construction of heterocyclic frameworks. The incorporation of the dimethylamino side chain in 1-3-(dimethylamino)propyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile introduces additional complexity to this synthetic route, requiring careful optimization of reaction conditions to achieve high yields and purity.

Recent computational studies have also explored the molecular docking interactions of 1-3-(dimethylamino)propyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile with potential target proteins. These simulations suggest that the carbonitrile group forms hydrogen bonds with key residues in the active site of target enzymes, while the hydroxyl group contributes to hydrophobic interactions. Such insights are critical for understanding the mechanism of action and guiding further medicinal chemistry efforts.

Despite its promising properties, the development of 1-3-(dimethylamino)propyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile as a therapeutic agent faces challenges related to its metabolic stability and potential toxicity. Ongoing research aims to address these issues through structural modifications, such as the introduction of fluoro or chloro substituents to enhance metabolic resistance. These efforts are part of a broader trend in drug discovery to improve the safety and efficacy of novel compounds.

In conclusion, 1-3-(dimethylamino)propyl-6-hydroxy-4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile represents a compelling example of how structural modifications can transform a classical pharmacophore into a multifunctional therapeutic agent. Its unique combination of 1,2-dihydropyridine and carbonitrile moieties, along with the presence of hydroxyl and methyl groups, positions it as a valuable candidate for further exploration in the treatment of complex diseases. Continued advancements in synthetic methods and biological studies will be essential for unlocking its full therapeutic potential.

• 11013-97-1(Methyl-Hesperidin)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)